| |
Multivariable-adjusted (Model 1)*
|
Multivariable-adjusted (Model 2)*
|
Multivariable-adjusted (Model 3)*
|
|---|
| |
HR (95% CI)
|
P-value
|
HR (95% CI)
|
P-value
|
HR (95% CI)
|
P-value
|
|---|
|
Age (in years)
|
|
65 - < 75
|
Ref
| |
Ref
| |
Ref
| |
|
75 - < 85
|
1.62 (1.60, 1.63)
|
< 0.0001
|
1.60 (1.58, 1.62)
|
< 0.0001
|
1.55 (1.53, 1.57)
|
< 0.0001
|
|
≥ 85
|
2.26 (2.23, 2.30)
|
< 0.0001
|
2.27 (2.24, 2.31)
|
< 0.0001
|
2.24 (2.21, 2.27)
|
< 0.0001
|
|
Gender
|
|
Male
|
Ref
| |
Ref
| |
Ref
| |
|
Female
|
0.78 (0.77, 0.79)
|
< 0.0001
|
0.78 (0.77, 0.78)
|
< 0.0001
|
0.76 (0.75, 0.76)
|
< 0.0001
|
|
Race
|
|
White
|
Ref
| |
Ref
| |
Ref
| |
|
Black
|
1.38 (1.36, 1.40)
|
< 0.0001
|
1.42 (1.39, 1.44)
|
< 0.0001
|
1.30 (1.28, 1.32)
|
< 0.0001
|
|
Other
|
0.98 (0.96, 1.00)
|
0.024
|
1.01 (0.99, 1.03)
|
0.46
|
0.96 (0.94, 0.98)
|
< 0.0001
|
|
Charlson-Romano score, per unit change
|
1.22 (1.21, 1.22)
|
< 0.0001
|
N/A
| |
N/A
| |
|
Charlson-Romano score
|
|
0
|
N/A
| |
Ref
| |
N/A
| |
|
1
| | |
2.33 (2.30, 2.37)
|
< 0.0001
| | |
|
≥ 2
| | |
2.99 (2.96, 3.02)
|
< 0.0001
| | |
|
Gout
|
3.05 (2.99, 3.10)
|
< 0.0001
|
2.96 (2.91, 3.01)
|
< 0.0001
|
2.59 (2.54, 2.63)
|
< 0.0001
|
- * Model 1 included Charlson-Romano score as a continuous variable; Model 2 replaced it with categorized Charlson-Romano score; and Model 3 replaced it with each of the 17 Charlson-Romano comorbidities. All models were also adjusted for medications for cardiovascular diseases (statins, beta-blockers, diuretics, ACE-inhibitors) and for urate-lowering therapies for gout (allopurinol, febuxostat)
- N/A not applicable, HR Hazard ratio, CI confidence interval, Ref referent category
- Bold represents statistical significance, with a P-value < 0.05
